Suketu Patel, MD
Ophthalmology · Newnan, GANPI 1629004791
Payments from drug & device makers
Across 237 payments — averaging $63.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$8K
- Alcon$2K
- Sun Pharmaceutical Industries Inc.$1K
- AbbVie$1K
- Johnson & Johnson Surgical Vision, Inc.$616
- Coopervision Inc.$500
- plus $2K from 19 others
What the payments were for
- Travel & lodging$8095%
- Food & beverage$6,13941%
- Education$5003%
- Other$7,50350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 3 | $7,669 |
| Alcon | 42 | $2,007 |
| Sun Pharmaceutical Industries Inc. | 42 | $1,043 |
| AbbVie(2 entities) | 49 | $1,022 |
| Johnson & Johnson Surgical Vision, Inc. | 23 | $616 |
| Coopervision Inc. | 2 | $500 |
| Novartis | 13 | $264 |
| Amgen | 9 | $213 |
| Eyevance Pharmaceuticals LLC | 2 | $183 |
| Aerie Pharmaceuticals, Inc. | 3 | $181 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $160 |
| Dompe US, Inc. | 6 | $155 |
| Atricure, Inc. | 1 | $145 |
| Kala Pharmaceuticals, Inc. | 6 | $136 |
| Glaukos Corporation | 3 | $132 |
| Bausch & Lomb Americas Inc. | 6 | $109 |
| Harrow Eye, LLC | 3 | $92 |
| Oyster Point Pharma, Inc. | 4 | $89 |
| Tarsus Pharmaceuticals, Inc. | 3 | $83 |
| Thea Pharma Inc. | 2 | $48 |
| Genentech USA, Inc. | 1 | $34 |
| Biotissue Holdings Inc. | 2 | $22 |
| Rxsight Inc | 1 | $17 |
| Omeros Corporation | 1 | $15 |
| Akorn, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMERA$7,503
- LenSx$809
- MiSight Contact Lens$500
- AcrySof IQ PanOptix UV IOL$186
- Tobradex ST$172
- VERACITY SURGICAL$166
- Clareon$149
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$145
- Clareon PanOptix Pro$139
- Rhopressa$124
- Rocklatan$124
- Tecnis IOL$118
- DURYSTA$106
- LUMIGAN$103
How this compares
$14,951 in reported general payments places this provider in the 85th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 149 | $156,519 |
| LumiganBimatoprost | 214 | $128,620 |
| Prednisolone Acetate | 548 | $29,807 |
| XiidraLifitegrast | 27 | $28,159 |
| Cyclosporine | 39 | $20,393 |
| ProlensaBromfenac Sodium | 59 | $20,084 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $19,430 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 86 | $13,067 |
| Latanoprost | 895 | $11,598 |
| Travoprost | 73 | $10,356 |
| Ketorolac Tromethamine | 301 | $8,422 |
| Alphagan PBrimonidine Tartrate | 32 | $7,895 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $7,451 |
| VyzultaLatanoprostene Bunod | 15 | $6,873 |
| Timolol Maleate | 251 | $5,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,022 | $312,465428 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $109 | $35,03242 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $160 | $20,08459 claims |
| AlconSimbrinza | $2,007 | $7,45122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Newnan
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.